中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 8
Aug.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(8): 1633-1638

Value of intestinal fatty acid binding protein in predicting the development and progression of acute-on-chronic liver failure

DOI: 10.12449/JCH240820
  • a.

    Department of Medical Laboratory, The Affiliated Hospital of Yanbian University，Yanji，Jilin 133000，China

  • b.

    Department of Gastroenterology, The Affiliated Hospital of Yanbian University，Yanji，Jilin 133000，China

  • c.

    Department of Infectious Diseases,The Affiliated Hospital of Yanbian University，Yanji，Jilin 133000，China

  • d.

    Department of Hepatobiliary Surgery，The Affiliated Hospital of Yanbian University，Yanji，Jilin 133000，China

Research funding:

Applied Foundation Research Project of Yanbian University (YDKJ202327);

Applied Foundation Research Project of Yanbian University (YDKJ202445)

More Information
  • Corresponding author: LI Guangyi， 1026481986@qq.com （ORCID： 0000-0002-6603-5244）
  • Received Date: 2023-12-24
  • Accepted Date: 2024-02-21
  • Published Date: 2024-08-25
    Abstract
  •   Objective  To investigate the value of intestinal fatty acid binding protein （I-FABP） in predicting the development and progression of acute-on-chronic liver failure （ACLF）.  Methods  A retrospective analysis was performed for the clinical data of 168 patients with decompensated liver cirrhosis who were admitted to The Affiliated Hospital of Yanbian University from September 2020 to March 2023. The conditions of the patients with ACLF on admission were observed， and the patients were followed up for 6 months to identify new-onset ACLF cases. ELISA was used to measure the serum level of I-FABP on admission. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H rank sum test was used for comparison between multiple groups； the chi-square test was used for comparison of categorical data between groups； the Jonckheere-Terpstra test was used for trend analysis. The Spearman correlation analysis was used to investigate the correlation between two variables， and the multivariate Cox regression analysis was used to investigate the influencing factors for new-onset ACLF during follow-up. The Kaplan-Meier curve was used to analyze the onset of ACLF in different groups， and the log-rank test was used for the analysis of such differences. The receiver operating characteristic （ROC） curve and the area under the ROC curve （AUC） were used to investigate the performance of I-FABP in predicting the development and progression of ACLF.  Results  Among the 168 patients enrolled in this study， there were 43 patients with ACLF and 125 patients without ACLF， among whom 19 developed ACLF during follow-up. The patients with ACLF on admission had a significantly higher level of I-FABP than those without ACLF （Z=4.359， P<0.001）. The patients with new-onset ACLF had a significantly higher level of I-FABP than those without new-onset ACLF （Z=3.414， P<0.001）. The level of I-FABP increased with the increase in ACLF severity grade （H=17.385， P<0.001，Ptrend<0.001）. The multivariate Cox regression analysis showed that I-FABP was independently associated with new-onset ACLF during follow-up （hazard ratio=2.138， 95% confidence interval ［CI］： 1.297 — 3.525， P=0.003）， and the tertile of I-FABP showed a good discriminatory ability （χ2=12.16， P<0.001）. The ROC curve showed that I-FABP had a good performance in predicting the development and progression of ACLF， with an area under the ROC curve of 0.854 （95%CI： 0.791 — 0.903） and 0.747 （95%CI： 0.661 — 0.820）， respectively， and an optimal cut-off value of 2.07 μg/L and 1.86 μg/L， respectively.  Conclusion  I-FABP can be used as a biomarker to predict the development and progression of ACLF， and it may help to identify high-risk patients and improve clinical management.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144( 7): 1426- 1437. e1- 1437. e9. DOI: 10.1053/j.gastro.2013.02.042.
    [2]
    KAMATH PS, KIM WR, GROUP ALDS. The model for end-stage liver disease(MELD)[J]. Hepatology, 2007, 45( 3): 797- 805. DOI: 10.1002/hep.21563.
    [3]
    JALAN R, SALIBA F, PAVESI M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure[J]. J Hepatol, 2014, 61( 5): 1038- 1047. DOI: 10.1016/j.jhep.2014.06.012.
    [4]
    CHEN MJ, LI X, TANG SH. Research progress on multidimensional evaluation of liver function in the prognosis of liver failure patients[J]. Clin J Med Offic, 2023, 51( 9): 901- 903, 907. DOI: 10.16680/j.1671-3826.2023.09.05.

    陈美娟, 李雪, 汤善宏. 多维度评估肝功能在肝衰竭患者预后中研究进展[J]. 临床军医杂志, 2023, 51( 9): 901- 903, 907. DOI: 10.16680/j.1671-3826.2023.09.05.
    [5]
    WANG P, ZHANG YJ, LI YR, et al. A correlation between gastrointestinal dysfunction and cirrhosis severity[J]. Medicine(Baltimore), 2018, 97( 37): e12070. DOI: 10.1097/MD.0000000000012070.
    [6]
    KALAITZAKIS E. Gastrointestinal dysfunction in liver cirrhosis[J]. World J Gastroenterol, 2014, 20( 40): 14686- 14695. DOI: 10.3748/wjg.v20.i40.14686.
    [7]
    BLASER AR, PREISER JC, FRUHWALD S, et al. Gastrointestinal dysfunction in the critically ill: A systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine[J]. Crit Care, 2020, 24( 1): 224. DOI: 10.1186/s13054-020-02889-4.
    [8]
    LOGAN M, MACKINDER M, CLARK CM, et al. Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease[J]. BMC Gastroenterol, 2022, 22( 1): 260. DOI: 10.1186/s12876-022-02334-6.
    [9]
    BLASER A, PADAR M, TANG J, et al. Citrulline and intestinal fatty acid-binding protein as biomarkers for gastrointestinal dysfunction in the critically ill[J]. Anaesthesiol Intensive Ther, 2019, 51( 3): 230- 239. DOI: 10.5114/ait.2019.86049.
    [10]
    TYSZKO M, LIPIŃ SKA-GEDIGA M, LEMAŃ SKA-PEREK A, et al. Intestinal fatty acid binding protein(I-FABP) as a prognostic marker in critically ill COVID-19 patients[J]. Pathogens, 2022, 11( 12): 1526. DOI: 10.3390/pathogens11121526.
    [11]
    SEILITZ J, EDSTRÖM M, KASIM A, et al. Intestinal fatty acid-binding protein and acute gastrointestinal injury grade in postoperative cardiac surgery patients[J]. J Card Surg, 2021, 36( 6): 1850- 1857. DOI: 10.1111/jocs.15430.
    [12]
    HAN CJ, WU ZX, HUANG Y, et al. Correlation between intestinal fatty acid-binding protein and bacterial infection as well as poor prognosis in patients with liver cirrhosis[J]. Chin J Infect Contr, 2023, 22( 3): 315- 321. DOI: 10.12138/j.issn.1671-9638.20233630.

    韩才均, 吴政燮, 黄媛, 等. 肠脂肪酸结合蛋白与肝硬化患者细菌感染和不良预后的相关性研究[J]. 中国感染控制杂志, 2023, 22( 3): 315- 321. DOI: 10.12138/j.issn.1671-9638.20233630.
    [13]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [14]
    FAN Q, LI Z. Liver transplantation for acute-on-chronic liver failure[J]. Ogran Transplant, 2022, 13( 3): 333- 337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.

    范祺, 李照. 慢加急性肝衰竭的肝移植治疗[J]. 器官移植, 2022, 13( 3): 333- 337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.
    [15]
    Liver Failure and ArtificiaI Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and ArtificiaI Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of Iiver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [16]
    HAN CJ, JIN X, WU ZX, et al. Predicting the prognosis of patients with HBV-related acute liver failure by combining the ratio of neutrophils to lymphocytes and the ratio of C-reactive protein to albumin[J]. Chin J Clin Lab Sci, 2022, 40( 4): 281- 285. DOI: 10.13602/j.cnki.jcls.2022.04.10.

    韩才均, 金星, 吴政燮, 等. 联合中性粒细胞与淋巴细胞比值和C反应蛋白与清蛋白比值预测HBV相关慢加急性肝衰竭患者预后[J]. 临床检验杂志, 2022, 40( 4): 281- 285. DOI: 10.13602/j.cnki.jcls.2022.04.10.
    [17]
    FUKUI H. Leaky gut and gut-liver axis in liver cirrhosis: Clinical studies update[J]. Gut Liver, 2021, 15( 5): 666- 676. DOI: 10.5009/gnl20032.
    [18]
    CHOPYK DM, GRAKOUI A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders[J]. Gastroenterology, 2020, 159( 3): 849- 863. DOI: 10.1053/j.gastro.2020.04.077.
    [19]
    OKADA K, SEKINO M, FUNAOKA H, et al. Intestinal fatty acid-binding protein levels in patients with chronic renal failure[J]. J Surg Res, 2018, 230: 94- 100. DOI: 10.1016/j.jss.2018.04.057.
    [20]
    TSAI IT, WU CC, HUNG WC, et al. FABP1 and FABP2 as markers of diabetic nephropathy[J]. Int J Med Sci, 2020, 17( 15): 2338- 2345. DOI: 10.7150/ijms.49078.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (125) PDF downloads(19) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return